Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2022-06-10 Major Shareholding Noti…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' submitted by Credit Suisse Group AG regarding their shareholding in Zealand Pharma A/S. It explicitly details the crossing of voting rights thresholds and share capital percentages, which is the definition of a Major Shareholding Notification (MRQ).
2022-06-10 English
Regulatory Filings 2022
Regulatory Filings Classification · 99% confidence The document is titled as a 'COMPANY ANNOUNCEMENT' and details the presentation of Phase 1 clinical trial data for a drug (dapiglutide) at a scientific session (ADA Scientific Sessions) and the subsequent announcement that the drug will move into a Phase 2 trial. This content structure—announcing clinical trial progress, safety profiles, and next steps—is characteristic of an Earnings Release (ER) or a general press release summarizing key operational and clinical milestones. Since it is not a full annual report (10-K), a formal audit report (AR), or a transcript (CT), and it focuses on immediate financial/operational news (clinical trial success/next phase), the most appropriate classification is Earnings Release (ER), as these announcements often accompany or precede formal earnings reports to highlight key business developments. It is not a Report Publication Announcement (RPA) because it contains substantial, detailed information about the trial results and future plans, rather than just announcing that a separate report is available.
2022-06-07 English
Share Issue/Capital Change 2022
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement titled "Zealand Pharma completes registration of capital increase." The content explicitly details the registration of a capital increase involving new shares resulting from a directed issue and private placement. This action directly relates to changes in the company's capital structure and financing activities. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a substantive announcement detailing the completion of a financing event, it is classified as CAP rather than a general Regulatory Filing (RNS).
2022-06-03 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 98% confidence The document explicitly announces a 'directed issue and private placement' of new shares, which corresponds to a capital raising or financing activity. Key phrases include 'directed issue', 'private placement', 'gross proceeds', and 'Company's cash runway is extended'. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it is the primary announcement detailing the financing terms and purpose, it is classified as CAP, not merely a Report Publication Announcement (RPA).
2022-06-01 English
Regulatory Filings 2022
Regulatory Filings Classification · 90% confidence The document is explicitly labeled as a 'PRESS RELEASE' and announces that Zealand Pharma will have multiple presentations at the 82nd Annual American Diabetes Association Scientific Sessions. It details the abstracts, session titles, dates, and authors for data related to their drug candidates (dapiglutide, ZP8396, dasiglucagon). This is not a full financial report (10-K or IR), nor is it a transcript (CT). It is an announcement about scientific data presentation, which is a common type of corporate communication. Since it is an announcement detailing upcoming scientific/clinical data presentations rather than a formal regulatory filing or a general earnings release, it fits best under the category of Investor Presentation (IP) if it were the presentation itself, or a general Regulatory Filing (RNS) if it were a miscellaneous announcement. However, given the context of scientific data being presented at a major conference, and the document structure being a press release announcing participation and data highlights, it is most closely aligned with an announcement about investor/scientific material. Since there is no specific code for 'Scientific Conference Announcement', and it is not a formal financial report, the closest fit among the provided options that covers corporate updates and scientific disclosures is often RNS (Regulatory Filings - general fallback) or potentially IP if the content were the presentation slides themselves. Since this is a press release *about* presentations, and not the presentation slides or a formal financial filing, RNS is the most appropriate general category for non-standard corporate news releases that don't fit ER, DIV, or CAP. However, the content is highly focused on R&D updates intended for investors and the scientific community. Given the options, and recognizing this is a standard press release format announcing scientific progress, RNS is the safest general classification for non-financial, non-management change announcements.
2022-05-31 English
Director's Dealing 2022
Director's Dealing Classification · 100% confidence The document is titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction (Grant of Warrants) involving a Senior Vice President (Christina S. Bredal) of the issuer (Zealand Pharma A/S) on a specific date (May 25, 2022). This content directly corresponds to the definition of reporting personal share transactions by company directors and executives, which is classified as Director's Dealing (DIRS).
2022-05-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.